Mei Ri Jing Ji Xin Wen·2025-08-12 06:40Core Insights - The Hong Kong innovative drug sector experienced a rebound after a dip, with the Hang Seng Innovative Drug Index down by 1.2% as of 14:00, while the Hang Seng Innovative Drug ETF (159316) saw a net subscription of 20 million units, indicating strong investor interest [1] Industry Overview - The Insight database released a list of the top 50 drug sales for the first half of 2025, highlighting that GLP-1 class drugs dominate the market and are a key driver of industry growth [1] - BeiGene's self-developed BTK inhibitor, Zebutine, ranked 46th on the sales list, marking the first time a domestic innovative drug has entered this ranking [1] Investment Opportunities - The commercialization process for innovative drugs is accelerating, presenting potential investment opportunities in related products [1] - Recent revisions to the Hang Seng Innovative Drug Index's compilation scheme have removed CXO companies, focusing solely on innovative drug firms, resulting in a "pure" index with 100% focus on innovative drugs [1] - Backtesting data shows that since the index's release on July 10, 2023, it has achieved higher annualized returns and Sharpe ratios following the adjustments [1] - The Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this index, providing a unique opportunity for investors to easily access leading innovative drug companies [1]